Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
O-Glutarylpsilocin
- Development stage
- Preclinical
- Lead developer
- Reunion Neuroscience
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
O-Glutarylpsilocin (developmental code name RE109) is a serotonergic psychedelic of the tryptamine family. It acts as a prodrug of psilocin (4-HO-DMT), similar to other psilocin prodrugs like 4-AcO-DMT and psilocybin. After administration, it is cleaved by non-specific esterases to release active psilocin in the body. The compound was first described in scientific literature in 2024 and has been patented by Reunion Neuroscience for potential use as an antidepressant or for other neuropsychiatric indications[2][8].
- Other names
- 4-glutaryloxy-N,N-dimethyltryptamine4-HO-DMT O-glutarate
02
Targets
HTR2C (5-hydroxytryptamine 2C receptor)HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on O-Glutarylpsilocin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on O-Glutarylpsilocin.